Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Study Summary

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

Conditions

C3G IC-MPGN Renal Transplant Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G)Dense Deposit Disease (DDD)Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulonephritis

Interventions / Drugs

Pegcetacoplan

View on ClinicalTrials.gov ↗

Sponsor

APLS

Apellis Pharmaceuticals

Complement Inhibitors

D36/100

Study Details

Enrollment13 participants

Primary Completion—

Lead SponsorApellis Pharmaceuticals, Inc.

Data Retrieved2026-04-11 02:54:08.046077+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.